SG11201908672WA - Compositions and methods for treating synucleinopathies - Google Patents

Compositions and methods for treating synucleinopathies

Info

Publication number
SG11201908672WA
SG11201908672WA SG11201908672WA SG11201908672WA SG 11201908672W A SG11201908672W A SG 11201908672WA SG 11201908672W A SG11201908672W A SG 11201908672WA SG 11201908672W A SG11201908672W A SG 11201908672WA
Authority
SG
Singapore
Prior art keywords
international
rule
pct
applicant
disease
Prior art date
Application number
Other languages
English (en)
Inventor
Natasha Penner
Kumar Kandadi Muralidharan
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of SG11201908672WA publication Critical patent/SG11201908672WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG11201908672W 2017-03-31 2018-03-30 Compositions and methods for treating synucleinopathies SG11201908672WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762479818P 2017-03-31 2017-03-31
US201762528790P 2017-07-05 2017-07-05
PCT/IB2018/052236 WO2018178950A1 (en) 2017-03-31 2018-03-30 Compositions and methods for treating synucleinopathies

Publications (1)

Publication Number Publication Date
SG11201908672WA true SG11201908672WA (en) 2019-10-30

Family

ID=62092178

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908672W SG11201908672WA (en) 2017-03-31 2018-03-30 Compositions and methods for treating synucleinopathies

Country Status (13)

Country Link
US (1) US20200377579A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630815A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020512368A (cg-RX-API-DMAC7.html)
KR (1) KR20200026789A (cg-RX-API-DMAC7.html)
CN (1) CN110997715A (cg-RX-API-DMAC7.html)
AU (1) AU2018242626A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019020335A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058304A1 (cg-RX-API-DMAC7.html)
IL (1) IL269637A (cg-RX-API-DMAC7.html)
JO (1) JOP20190227A1 (cg-RX-API-DMAC7.html)
MA (1) MA48730A (cg-RX-API-DMAC7.html)
SG (1) SG11201908672WA (cg-RX-API-DMAC7.html)
WO (1) WO2018178950A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
CA3076313A1 (en) * 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
BR112021006123A2 (pt) * 2018-10-19 2021-07-20 Janssen Vaccines & Prevention B.V. anticorpos anti-sinucleína
MX2022006676A (es) * 2019-12-04 2022-07-05 Ac Immune Sa Nuevas moleculas para terapia y diagnostico.
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
TW202227131A (zh) 2020-09-10 2022-07-16 愛爾蘭商普羅佘納生物科技有限公司 帕金森氏症之治療
IL311344A (en) 2021-09-16 2024-05-01 H Lundbeck As Preparations and methods for the treatment of synoclinopathies
JP2026506882A (ja) * 2023-02-06 2026-02-27 クリエイティブ バイオ-ぺプタイズ インコーポレイテッド 神経学的障害を処置するためのペプチド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
HRP20150831T1 (hr) * 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
PL2723379T3 (pl) * 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн

Also Published As

Publication number Publication date
BR112019020335A2 (pt) 2020-04-28
CN110997715A (zh) 2020-04-10
JP2020512368A (ja) 2020-04-23
MA48730A (fr) 2020-04-08
WO2018178950A1 (en) 2018-10-04
US20200377579A1 (en) 2020-12-03
JOP20190227A1 (ar) 2019-09-30
CA3058304A1 (en) 2018-10-04
IL269637A (en) 2019-11-28
KR20200026789A (ko) 2020-03-11
AU2018242626A1 (en) 2019-10-10
EP3630815A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201908393YA (en) Modulators of pcsk9 expression
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808686VA (en) Synthesis of indazoles
SG11201804587QA (en) Isoindole compounds
SG11201908159QA (en) Dual magl and faah inhibitors